Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

SML0527

Sigma-Aldrich

Epalrestat

≥98% (HPLC)

Sinônimo(s):

(5Z)-5-[(2E)-2-Methyl-3-phenyl-2-propen-1-ylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid

Faça loginpara ver os preços organizacionais e de contrato


About This Item

Fórmula empírica (Notação de Hill):
C15H13NO3S2
Número CAS:
Peso molecular:
319.40
Código UNSPSC:
12352200
NACRES:
NA.77

Ensaio

≥98% (HPLC)

Formulário

powder

condição de armazenamento

protect from light

cor

yellow to orange

solubilidade

DMSO: 5 mg/mL, clear (warmed)

temperatura de armazenamento

−20°C

cadeia de caracteres SMILES

S1\C(=C/C(=C/c2ccccc2)/C)\C(=O)N(C1=S)CC(=O)O

InChI

1S/C15H13NO3S2/c1-10(7-11-5-3-2-4-6-11)8-12-14(19)16(9-13(17)18)15(20)21-12/h2-8H,9H2,1H3,(H,17,18)/b10-7+,12-8-

chave InChI

CHNUOJQWGUIOLD-NFZZJPOKSA-N

Aplicação

Epalrestat has been used as an aldose reductase inhibitor:
  • in the dahomey larvae diet fed forDrosophila
  • for non-irradiated and X-ray irradiated human aldose reductase
  • to test its protective effect in mice with bleomycin-induced pulmonary fibrosis

Ações bioquímicas/fisiológicas

Epalrestat inhibits Aldose Reductase (AR) involved in the rate limiting step in the conversion of glucose to sorbitol under hyperglycemic conditions. Aldose reductase has been the target of multiple clinical investigatons to treat diabetic neuropathy and retinopathy. Epalrestat is an approved drug in Japan and India, used for the treatment of diabetic neuropathy.
Epalrestat is an Aldose Reductase inhibitor.

Características e benefícios

This compound is featured on the Dopamine and Norepinephrine Metabolism page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Outras notas

Light sensitve

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable


Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

Não está vendo a versão correta?

Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

Slide 1 of 6

1 of 6

Vincenzo Calderone et al.
The Journal of pharmacy and pharmacology, 62(1), 107-113 (2010-08-21)
Many observations report the cardioprotective effects of inhibitors of aldose reductase in different models of ischaemia-reperfusion injury in diabetic myocardium. In this paper, the inhibitory effects of the new pyrido[1,2-a]-pyrimidin-4-one derivative PPO, whose aldose reductase-inhibitory and antioxidant effects were shown
J W Steele et al.
Drugs & aging, 3(6), 532-555 (1993-11-01)
Epalrestat is a carboxylic acid derivative which inhibits aldose reductase, an enzyme of the sorbitol (polyol) pathway. Under hyperglycaemic conditions epalrestat reduces intracellular sorbitol accumulation, which has been implicated in the pathogenesis of late-onset complications of diabetes mellitus. Epalrestat 150
Ramakrishna Nirogi et al.
Journal of pharmaceutical and biomedical analysis, 74, 227-234 (2012-12-19)
A simple and rapid LC-MS/MS method was developed and validated for the quantification of epalrestat, an aldose reductase inhibitor for the treatment of diabetic neuropathy. Following protein precipitation epalrestat and IS were eluted with 10mM ammonium acetate and acetonitrile using
Mary Ann Ramirez et al.
Pharmacotherapy, 28(5), 646-655 (2008-05-02)
Diabetic neuropathy is one of the most common long-term complications in patients with diabetes mellitus, with a prevalence of 60-70% in the United States. Treatment options include antidepressants, anticonvulsants, tramadol, and capsaicin. These agents are modestly effective for symptomatic relief
Bruno Bulic et al.
Neuropharmacology, 59(4-5), 276-289 (2010-02-13)
Alzheimer disease is characterized by pathological aggregation of two proteins, tau and Abeta-amyloid, both of which are considered to be toxic to neurons. In this review we summarize recent advances on small molecule inhibitors of protein aggregation with emphasis on

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica